ABPRO HOLDINGS INC (ABP) Stock Price, Forecast & Analysis
USA - NASDAQ:ABP - US0008471031 - Common Stock
ABP Key Statistics, Chart & Performance
The current stock price of ABP is 5.52 USD. In the past month the price increased by 1.81%.
ABP Latest News, Press Relases and Analysis
ABP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.13 | 386.12B | ||
| AMGN | AMGEN INC | 14.74 | 173.56B | ||
| GILD | GILEAD SCIENCES INC | 14.38 | 146.16B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.78 | 105.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.68 | 70.01B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 874.73 | 58.48B | ||
| INSM | INSMED INC | N/A | 39.85B | ||
| NTRA | NATERA INC | N/A | 28.41B | ||
| BIIB | BIOGEN INC | 9.25 | 22.70B | ||
| INCY | INCYTE CORP | 16.29 | 20.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.93 | 20.20B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.81 | 14.85B |
Related stock screener links
About ABP
Company Profile
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Company Info
ABPRO HOLDINGS INC
6 St Johns Lane, Floor 5
New York City NEW YORK US
Employees: 6
Phone: 12488907200
ABPRO HOLDINGS INC / ABP FAQ
What does ABP do?
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
What is the current price of ABP stock?
The current stock price of ABP is 5.52 USD. The price decreased by -1.78% in the last trading session.
Does ABPRO HOLDINGS INC pay dividends?
ABP does not pay a dividend.
What is the ChartMill rating of ABPRO HOLDINGS INC stock?
ABP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ABP stock?
ABPRO HOLDINGS INC (ABP) operates in the Health Care sector and the Biotechnology industry.
Would investing in ABPRO HOLDINGS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABP.
ABP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ABP.
ABP Financial Highlights
Over the last trailing twelve months ABP reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS decreased by -2966.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -396% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |